전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,047 programs
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Preclinical

CD19-CART (CD19-CART)

Autoimmune Disease · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 2Status Recruiting
CGTLimited DatastaleTimmune Biotech Inc.Phase 1

CD19-TriCAR-T/SILK (CD19-TriCAR-T/SILK)

Non-Hodgkin Lymphoma of Intestine; Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 2Status Active
CGTLimited DatastaleChina Immunotech Pharmaceutical…Phase 1

CD19/CD20 Dual-CAR-T cells (CD19/CD20 Dual-CAR-T cells)

B-cell Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 2Status Active
CGTLimited DatastaleUniversity of Colorado, DenverPhase 1

CD19x22 CAR T Cells (CD19x22 CAR T Cells)

Non-Hodgkin Lymphoma; B-cell Non-Hodgkin Lymphoma (B-NHL) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
CGTLimited DatastaleOneChain ImmunotherapeuticsPhase 1

CD1a-CAR T (CD1a-CAR T)

T-cell Acute Lymphoblastic Leukemia; Lymphoblastic T-Cell Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 2Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 2

CDX-3379 and cetuximab (CDX-3379 and cetuximab)

Advanced Head and Neck Squamous Cell Carcinoma · Advanced Head and Neck Squamous Cell Car

#AdvancedHeadandNeckSquamousCellC#Antibody#Phase2#monoclonal-antibody#Eli
Trials 2Status Discontinued
CGTLimited DatastaleBiohaven Pharmaceuticals, Inc.Phase 2

CIML NK Cell Infusion (CIML NK Cell Infusion)

Squamous Cell Carcinoma of the Head and Neck; Recurrent Head and Neck Squamous Cell Carcinoma · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Active
CGTLimited DatastaleIntima Bioscience, Inc.Phase 2

CISH Inactivated TIL (CISH Inactivated TIL)

Carcinoma, Non-Small-Cell Lung; Metastatic Non Small Cell Lung Cancer · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 2Status Discontinued
CGTLimited DatastaleGuangzhou Bio-gene Technology C…Phase 1

CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells (CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells)

Non Small Cell Lung Cancer · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 2Status Recruiting
AntibodyLimited DatastaleRochePhase 3

China-approved Bevacizumab (China-approved Bevacizumab)

Metastatic Colorectal Cancer (CRC) · Advanced Non-squamous Non-small-cell Lun

#AdvancedNon-squamousNon-small-ce#Antibody#Phase3#monoclonal-antibody#MetastaticColorectalCancerCRC+1
Trials 2Status Active
CGTLimited DatastaleFrontiergate Biopharm（Hainan） C…Phase 1

Claudin18.2-targeted CAR-DCs (Claudin18.2-targeted CAR-DCs)

Colorectal Neoplasia · Colorectal Neoplasia

#ColorectalNeoplasia#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 2Status Recruiting
AntibodyLimited DatastaleAbbViePhase 1

Cofetuzumab Pelidotin (Cofetuzumab Pelidotin)

Cancer; Non-small Cell Lung Cancer (NSCLC) · Cancer

#Cancer#Antibody#Phase1#monoclonal-antibody#Non-smallCellLungCancerNSCLC+1
Trials 2Status Discontinued
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab (Keytruda, Coformulated vibostolimab/pembrolizumab)

Metastatic Urothelial Carcinoma; Urothelial Neoplasms · Metastatic Urothelial Carcinoma

#MetastaticUrothelialCarcinoma#Antibody#Phase2#monoclonal-antibody#UrothelialNeoplasms+1
Trials 2Status Recruiting
AntibodyLimited DatastaleHoffmann-La RocheApproved

Daclizumab (Daclizumab)

Type 1 Diabetes Mellitus · Myelodysplastic Syndromes

#MyelodysplasticSyndromes#Antibody#Approved#monoclonal-antibody#Type1DiabetesMellitus+1
Trials 2Status Active
AntibodyLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Dalotuzumab (Dalotuzumab)

Rectal Neoplasms · Rectal Neoplasms

#RectalNeoplasms#Antibody#Phase2#monoclonal-antibody#Merck
Trials 2Status Active
CGTLimited DatastaleHan weidongPhase 2

Decitabine-primed Tandem CAR19/20 engineered T cells (Decitabine-primed Tandem CAR19/20 engineered T cells)

Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
CGTLimited DatastaleImmune Design, a subsidiary of …Phase 1

Dendritic Cell-targeting Lentiviral Vector ID-LV305 (Dendritic Cell-targeting Lentiviral Vector ID-LV305)

HLA-A*0201 Positive Cells Present; NY-ESO-1 Positive Tumor Cells Present · HLA-A*0201 Positive Cells Present

#HLA-A0201PositiveCellsPresent#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 2Status Active
AntibodyLimited DatastalePeking UniversityPhase 2

Dexamethasone, azacytidine, Pegaspargase, Tislelizumab (Dexamethasone, azacytidine, Pegaspargase, Tislelizumab)

NK/T Cell Lymphoma · NK/T Cell Lymphoma

#NKTCellLymphoma#Antibody#Phase2#monoclonal-antibody#NK+2
Trials 2Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy)

Gastric Cancer · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#GastricCancer+1
Trials 2Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Bicalutamide)

Extramammary Paget Disease; Scrotum Disease · Extramammary Paget Disease

#ExtramammaryPagetDisease#ADC#Phase2#antibody-drug-conjugate#ScrotumDisease+1
Trials 2Status Recruiting

33 / 103 pages

← PreviousNext →